This page is not the official website. Generated by AI, does not constitute any advice. If needed, please click here to visit the corresponding official website.
A visionary diagnostic company dedicated to transforming the landscape of cancer care. We are driven by innovation, accessibility, collaboration, and integrity.
A visionary diagnostic company dedicated to transforming the landscape of cancer care. 'Breaking Barriers to Precision Oncology' reflects our commitment to revolutionizing cancer diagnosis and treatment.
Innovation in Care: Developing groundbreaking diagnostic tools for precision oncology.
Accessibility and Equity: Ensuring advanced diagnostics are available globally.
Collaboration and Partnership: Working closely with pharma and clinical labs.
Integrity and Trust: Delivering reliable, accurate, and ethically developed solutions.
To provide our customers with superior and innovative products and services to improve healthcare and patients' lives.
To be one of the global leading and most reliable suppliers of high-quality molecular diagnostic solutions in oncology.
Proprietary platforms enabling precision, speed, and accessibility in cancer diagnostics.
Every Strand Matters — highly efficient NGS library prep with minimal sample input.
Making Complex NGS Testing Easy to HANDLE — simplified workflow for broad adoption.
No Sequencing Needed — rapid PCR-based mutation detection with high specificity.
Sensitivity Increased to 0.2% — detects ultra-low frequency mutations in liquid biopsy.
Comprehensive molecular diagnostic solutions for precision oncology.
Leveraging HANDLE tech and GSS algorithm for accurate HRD scoring in PARPi therapy.
Comprehensive HRD test for clinical research with full genomic scar analysis.
Leading CGP assay covering HRD, MSI, TMB, and 500+ cancer genes.
Detects germline/somatic SNVs/Indels and large rearrangements in BRCA1/2.
40 key solid tumor genes for rapid clinical decision support.
Detects key mutations in 10 genes for NSCLC and colorectal cancer.
Approved in Japan as CDx for Lorlatinib, Taletrectinib, and Amivantamab.
Performance evaluation completed for liquid biopsy-based breast cancer profiling.
Stay updated with the latest in molecular diagnostics and oncology testing.
For inquiries about our products, partnerships, or support, visit our official website.
Address: 2 Science Park Drive, Ascent #01-08, Singapore 118222
Email: info@amoydx.com
Notice for Buyers: If you are a buyer, the above information is generated by AI collection and does not constitute any advice. If necessary, please visit the corresponding official website.
For Domain Owners: If you are the domain owner and do not want to be included by fobcompany.info, please contact support@fobcompany.info via your corporate email to cancel. We will cancel your inclusion within 3 business days.
如果您是域名所有者 不想被fobcompany.info收录 请用企业邮箱联系support@fobcompany.info 取消收录 我们将在3个工作日取消您的收录
Service Request: If you are other domain and want to be included, please contact support@fobcompany.info
如果您是其他域名合作 也请联系support@fobcompany.info